Induction of remission of idiopathic anaphylaxis with rituximab - 02/10/14
Disclosure of potential conflicts of interest: A. Borzutzky has been a speaker for Roche and Novartis Laboratories (Chile); has received research support from Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT grant nos. 1130615 and 1130387) (Chile) and FONIS (grant no. SA13I20173) (Chile); has received lecture fees from Roche Laboratories (Chile) and Pfizer (Chile); and has received travel support from Pfizer (Chile) and Abbott Laboratories (Chile). V. Mezzano has received lecture fees from Brystol-Myers Squibb and has received support for travel, accommodations, and meeting registration from Janssen. A. W. Burks is or has been on the board for Food Allergy Research and Education, the American Academy of Allergy, Asthma & Immunology, and the Food Allergy Initiative; has received consultancy fees from Dynavax Technologies Corp, Genalyte, GLG Research, Perrigo Company, Regeneron Pharmaceuticals, Perosphere Inc, Dow AgroSciences, ExploraMed Development, McNeil Nutritionals, Merck, Nordic Biotech, Norvartis Pharma AG, Nutricia North American, Portola Pharaceuticals, Publicis Healthcare Communications Group, and Unilever; has received research support from Hycor Biomedical; has received lecture fees from Abbott Laboratories, the American College of Allergy, Asthma, and Immunology, and Mylan Speciality; has received royalties from UpToDate; has received payment for development of educational presentations from Levine Children's Hospital and Oak Ridge Associated Universities; and has stock/stock options in Allertein and MastCell Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 134 - N° 4
P. 981-983 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?